ArticleRadiation oncology (London, England)2025
Validation and refinement of the 8th edition of the AJCC staging system for esophageal squamous cell carcinoma treated with definitive IMRT or chemo-IMRT: a Chinese multi-institutional retrospective study.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiac substructure dosimetry in thoracic radiotherapy: moving beyond mean heart dose and toward precision cardiac risk mitigation.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
objectiveThis study evaluated the 8th edition American Joint Committee on Cancer (AJCC) staging system for esophageal squamous cell carcinoma (ESCC) and developed an improved staging framework using automated recursive partitioning analysis (autoRPA).
methodsThis retrospective study included 2773 ESCC patients treated with definitive intensity-modulated radiation therapy (IMRT) or chemo-IMRT across 8 Chinese centers (2001-2019). Kaplan‒Meier curves and log-rank tests were used to assess overall survival (OS). AutoRPA-derived stage groupings were optimized via the revised T/N criteria. The proposed staging was compared with the 8th edition AJCC staging via hazard discrimination, consistency, sample balance, and predictive accuracy.
resultsThe 3-year, and 5-year rates for the entire cohort were 43.5%, and 34.0%, respectively. The AJCC T4a/T4b stages exhibited overlapping OS curves, prompting their consolidation into a single T4 stage. While the AJCC N2 and N3 stages showed overlapping OS curves, supraclavicular lymph node (SLN) metastasis independently predicted worse OS than N2, with outcomes similar to those of N3. Location-based SLN classification further refined nodal staging, with cervical esophageal-SLN metastasis classified as N1, upper thoracic-SLN metastasis as N2, and middle or lower thoracic-SLN metastasis as N3, yielding distinct OS stratification. The autoRPA-derived staging outperformed the 8th edition AJCC staging in hazard consistency, sample balance, and predictive accuracy, with RPA-I exhibiting distinctly sharper OS curves than other stages.
conclusionCombining T4a/T4b and SLN subclassification enhanced prognostic precision in ESCC, with the autoRPA staging demonstrating superior hazard consistency, sample balance, and predictive accuracy compared to the 8th edition AJCC staging, thereby guiding therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.